Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8426469 | 0.94 | ALDH1A1 (0.37) | ALDH1A1MAPK1METAP2 | |
| SCHEMBL8424725 | 0.80 | CA1 (0.42) | ALDH1A1MAPK1TDP1CA1CA2 | |
| SCHEMBL4912359 | 0.78 | TDP1 (0.46) | ALDH1A1TDP1CA1CA2 | |
| SCHEMBL8426506 | 0.77 | CA2 (0.58) | MAPK1CA1CA2 | |
| SCHEMBL7376546 | 0.76 | CA2 (0.49) | MAPK1TDP1CA1CA2 | |
| SCHEMBL8427664 | 0.74 | ACACB (0.33) | ALDH1A1MAPK1TDP1CYP2C9CYP1A2 | |
| SCHEMBL14348564 | 0.74 | ACACB (0.33) | ALDH1A1MAPK1TDP1CYP2C9CYP1A2 | |
| SCHEMBL8426505 | 0.73 | ALDH1A1 (0.34) | ALDH1A1CA1CA2MCL1 | |
| SCHEMBL7370650 | 0.73 | TDP1 (0.40) | TDP1CYP2D6CA1CA2 | |
| SCHEMBL7371375 | 0.73 | TSHR (0.41) | TDP1CYP2D6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | ALDH1A1 1335/4885MAPK1 2198/4885TDP1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.